



PATIENT INFORMATION SHEET

CureMatch, Inc.
6370 Lusk Blvd., Ste. F208
San Diego, CA 92121, USA
Phone: 858-859-CURE
www.curematch.com
Email: info@curematch.com

CureMatch is the only company to offer a report that guides oncologists in the selection of personalized combination therapies, using supercomputing and the latest discoveries in genomics and proteomics. CureMatch analyzes more than 4.5 million different drug combinations to find and rank the most advanced cancer treatments, customized specifically for the individual patient. The technology was originally developed at the UCSD Moores Cancer Center and San Diego Supercomputer Center to guide clinical decision-making when discussing potential therapy options for patients with complex cases.

Why Personalized Cancer Therapy?

Doctors and patients have traditionally relied upon “one-size-fits-all” treatments, such as chemotherapy, aimed largely at fighting a particular type of cancer, such as liver, lung, or colorectal cancer. However, decades of cancer research and treatment have demonstrated that each patient’s cancer is unique, and that two patients with the same cancer diagnosis rarely have similar reactions to identical treatments. Thus, cancer can truly be viewed as a personal disease.

Personalized medicine is an emerging approach for disease treatment and prevention that takes into account individual variability in environment, lifestyle, and genes for each person. Molecular profiling techniques, such as DNA sequencing, have greatly accelerated the identification of patient- and tumor-specific mutations, and have enabled personalized medicine to become a reality in oncology. Personalized medicine now allows doctors to customize cancer treatments for individual patients, bringing the potential of increased survival rates, improved quality of life, and fewer side effects to the treatment.


Why Combination Therapy?

CureMatch focuses on Personalized Combination Therapy, in which a combination of drugs is used to treat cancer. Cancer has historically been treated using standard single drug therapies to target specific cancers, and even when using personalized cancer therapy, the vast majority of treatments are performed using targeted monotherapies that focus only on the “driver” mutation and ignore the “passenger” mutations. Recently, it has been shown that when the right combination of multiple drugs is used to match multiple mutations, cancer treatment can be more effective. Each drug is able to target individual cancer mutations to improve treatment, and each drug can be used with the right dose to reduce side effects.

Combination therapy has been widely used for treatment and/or prevention of other diseases, such as infectious diseases, cardiovascular diseases, diabetes, and Alzheimer’s disease, and has proven to be particularly effective for the treatment of HIV/AIDS. Unfortunately, combination therapy is not widely available for oncology, primarily because there are millions of possible drug combinations that are difficult for oncologists and tumor boards to analyze. However, there is growing evidence that personalized combination therapy is the future of oncology.

The CureMatch Approach

With more than 4.5 million possible drug combination options, determining the optimal combination therapy for an individual patient’s cancer is an extremely daunting task for a doctor —and it is this obstacle to combination therapy that the CureMatch platform is specifically designed to address. The goal of CureMatch is to make it simple for any oncologist to consider Personalized Combination Therapy options for any patient, regardless of the organ of origin, stage of cancer, or complexity of the tumor’s molecular profile. The specific steps are provided below.



Who is Eligible for the CureMatch Analysis?

The CureMatch test is available for patients with all types of cancer and at all stages. In many cases, patients will have already undergone surgery, radiation therapy, and/or one or more lines of chemotherapy.

What is Needed for the CureMatch Analysis?

Molecular profiling data from the patient’s tumor is required prior to CureMatch analysis. CureMatch is able to process various types of molecular profiling data, all listed in the table below. The most common type is DNA sequencing data, specifically using Next-Generation Sequencing methods.

Several companies offer molecular profiling services. These include, but are not limited to, Ambry Genetics, Cancer Genetics, Caris, Clariant, Foundation Medicine, GenomeDX, Genomic Health, Guardant, InterMountain, NantOmics, NeoGenomics, Perthera, and Trovagene. The specific molecular profiling service that a patient uses depends on a number of factors. Talk to your oncologist to decide which test is best for you, or contact us if you would like us to refer you to an oncologist who can help you decide.

Which Drug and Treatment Options does CureMatch Analyze?

CureMatch's system looks at all FDA-approved drugs and pharmacology classes, including immunotherapies.

Where do I get More Information?

For more information, please contact CureMatch at 858-859-CURE or info@curematch.com, or visit us online on our website at www.curematch.com.